Osteoporosis
Conditions
Interventions
None listed
Sponsors
Contact for Post-marketing surveillance and relate studies
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients meeting all of the following conditions are to be enrolled in the cohorts: Patients receiving a diagnosis of osteoporosis during the enrollment period (from January 2023 through December 2027) and who were newly prescribed with OSTABALO or the control drug in the same month as they received the diagnosis of osteoporosis. In the case that OSTABALO or the control drug is prescribed for a patient previously unprescribed with either drug during the 180 days prior to and including the day before the prescription date of OSTABALO or the control drug, this is regarded as a new prescription. Medical records available for at least 180 days prior to the initial follow-up date (see "13.4.2 Definition of Initial Follow-up Date").
Exclusion criteria
Exclusion criteria: Patients meeting the following criterion are to be excluded from this survey: Patients who were prescribed with OSTABALO and the control drug at the same date as the initial follow-up date.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composite cardiovascular events including intracerebral hemorrhage, cerebral infarction, and acute coronary syndrome | — |
Secondary
| Measure | Time frame |
|---|---|
| Each component of the composite endpoint of cardiovascular events | — |
Contacts
Public ContactContact for
Teijin Pharma Limited
Outcome results
None listed